author-photo

Thomas M. Jahn

Children's Hospital Los Angeles

35

Papers

2442

Citations

Citation Trend

Filter By

Papers (26) Sort By

Journal Conference Others

Phase 1b study of venetoclax in combination with azacitidine in patients with treatment-naïve higher-risk myelodysplastic syndromes.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Second Interim Analysis of a Phase 3 Study Evaluating Idelalisib and Rituximab for Relapsed Chronic Lymphocytic Leukemia

2015 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Long-term follow-up of a phase Ib trial of idelalisib (IDELA) in combination with chemoimmunotherapy (CIT) in patients (pts) with relapsed/refractory (R/R) CLL including pts with del17p/TP53 mutation.

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (9)
Health-related quality of life (HRQL) impact of idelalisib (IDELA) in patients (pts) with relapsed chronic lymphocytic leukemia (CLL): Phase 3 results.

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
A phase 3, randomized, double-blind, placebo-controlled study evaluating the efFicacy and safely or idelalisib (GS-1101) in combination with bendamustine and Minimal) for previously treated chronic lymphocytic leukemia (CLL).

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed chronic lymphocytic leukemia

2014 Journal of Geriatric Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

2014 Blood
Show All
- Source
- Cite
- Save
Citations (466)
Long-Term Follow-up of a Phase 1 Study of Idelalisib (ZYDELIG®) in Combination with Anti-CD20 Antibodies (Rituximab [R] or Ofatumumab [O]) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

2014 Blood
Show All
- Source
- Cite
- Save
Citations (6)
Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL.

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (9)
Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIG®) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors

2014 Blood
Show All
- Source
- Cite
- Save
Citations (71)